This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
TCR2 Therapeutics Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for TCR2 Therapeutics.
Key information
-5.2%
Earnings growth rate
22.7%
EPS growth rate
Biotechs earnings growth | 35.1% |
Revenue growth rate | 74.0% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 01 Jun 2023 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 13 | -235 | N/A | N/A | 1 |
12/31/2024 | N/A | -136 | N/A | N/A | 2 |
12/31/2023 | N/A | -113 | N/A | N/A | 4 |
3/31/2023 | N/A | -163 | -124 | -110 | N/A |
12/31/2022 | N/A | -152 | -117 | -101 | N/A |
9/30/2022 | N/A | -119 | -120 | -100 | N/A |
6/30/2022 | N/A | -115 | -111 | -93 | N/A |
3/31/2022 | N/A | -107 | -101 | -89 | N/A |
12/31/2021 | N/A | -100 | -93 | -82 | N/A |
9/30/2021 | N/A | -91 | -81 | -72 | N/A |
6/30/2021 | N/A | -81 | -72 | -63 | N/A |
3/31/2021 | N/A | -73 | -72 | -64 | N/A |
12/31/2020 | N/A | -67 | -64 | -57 | N/A |
9/30/2020 | N/A | -61 | -57 | -54 | N/A |
6/30/2020 | N/A | -58 | -57 | -53 | N/A |
3/31/2020 | N/A | -53 | -51 | -47 | N/A |
12/31/2019 | N/A | -97 | -45 | -41 | N/A |
9/30/2019 | N/A | -96 | -41 | -37 | N/A |
6/30/2019 | N/A | -100 | -33 | -32 | N/A |
3/31/2019 | N/A | -107 | -27 | -27 | N/A |
12/31/2018 | N/A | -62 | -20 | -19 | N/A |
9/30/2018 | N/A | -55 | -18 | -17 | N/A |
12/31/2017 | N/A | -15 | -12 | -12 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2K7 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2K7 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2K7 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2K7 is forecast to have no revenue next year.
High Growth Revenue: 2K7 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 2K7's Return on Equity is forecast to be high in 3 years time